Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Hea...(dicallyunderserved portion of America's ...),Health

Date:5/12/2008

dically underserved portion of America's population. It is vital that American women are aware of diseases more common in women, take care of their health, and talk to their doctors about symptoms that might be part of a more serious condition," says ALR's Scientific Advisory Board Chair, Dr. Mary K. Crow. "Lupus can cause heart and kidney disease - two leading causes of death for women - so we are grateful to our Members of Congress for shining a light on this important issue."

The Alliance for Lupus Research (ALR) is a national voluntary health organization based in New York City and founded in 1999. Chaired by Robert Wood Johnson IV, it has become the world's largest private source of lupus research funds and has committed $50 million to lupus-specific research projects since its inception. The organization's mission is to find better treatments and ultimately prevent and cure lupus by supporting medical research. Because the ALR's Board of Directors pays for all administrative and fundraising costs, 100% of all donations go directly to support lupus research programs. For more information, visit http://www.lupusresearch.org.

'/>"/>

SOURCE Alliance for Lupus Research Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
2. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
3. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
6. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
7. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Aida Announces New Anti-Cancer Drug Under Development
10. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
11. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses